Inventiva (IVA) Competitors $3.07 +0.05 (+1.66%) Closing price 04/4/2025 03:53 PM EasternExtended Trading$3.29 +0.22 (+7.17%) As of 04/4/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. TRVI, NUVB, BCYC, IMNM, DNTH, PHAR, GHRS, KALV, VECT, and QUREShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Immunome (IMNM), Dianthus Therapeutics (DNTH), Pharming Group (PHAR), GH Research (GHRS), KalVista Pharmaceuticals (KALV), VectivBio (VECT), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Trevi Therapeutics Nuvation Bio Bicycle Therapeutics Immunome Dianthus Therapeutics Pharming Group GH Research KalVista Pharmaceuticals VectivBio uniQure Inventiva (NASDAQ:IVA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Is IVA or TRVI more profitable? Inventiva's return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Trevi Therapeutics N/A -63.31%-57.06% Does the MarketBeat Community favor IVA or TRVI? Trevi Therapeutics received 81 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 67.74% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2482.76% Underperform Votes517.24%Trevi TherapeuticsOutperform Votes10567.74% Underperform Votes5032.26% Which has stronger valuation & earnings, IVA or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.20M17.52-$119.51MN/AN/ATrevi TherapeuticsN/AN/A-$29.07M-$0.47-12.87 Do insiders and institutionals hold more shares of IVA or TRVI? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer IVA or TRVI? Inventiva currently has a consensus price target of $12.00, suggesting a potential upside of 290.88%. Trevi Therapeutics has a consensus price target of $17.56, suggesting a potential upside of 190.29%. Given Inventiva's higher possible upside, analysts clearly believe Inventiva is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30 Does the media refer more to IVA or TRVI? In the previous week, Inventiva had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Inventiva and 5 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.63 beat Inventiva's score of -0.04 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, IVA or TRVI? Inventiva has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. SummaryInventiva beats Trevi Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.10M$6.35B$5.26B$7.12BDividend YieldN/A2.85%4.89%4.08%P/E RatioN/A6.8321.3817.50Price / Sales17.52187.43355.0687.33Price / CashN/A65.6738.1834.64Price / Book-4.585.576.233.79Net Income-$119.51M$141.89M$3.21B$247.48M7 Day Performance4.74%-11.51%-8.47%-6.79%1 Month Performance8.29%-16.59%-4.87%-11.53%1 Year Performance-18.78%-18.14%2.54%-7.82% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva1.6612 of 5 stars$3.07+1.7%$12.00+290.9%-16.1%$161.10M$9.20M0.00100Analyst ForecastNews CoverageTRVITrevi Therapeutics3.5182 of 5 stars$6.29-3.2%$17.56+179.2%+94.5%$608.13MN/A-14.3020Short Interest ↑Gap DownHigh Trading VolumeNUVBNuvation Bio1.5541 of 5 stars$1.78-2.5%$8.75+393.0%-52.3%$601.16M$7.87M-0.8260BCYCBicycle Therapeutics1.4406 of 5 stars$8.49-5.4%$29.14+243.3%-69.5%$587.53M$35.28M-2.58240Gap DownIMNMImmunome2.5303 of 5 stars$6.73-3.7%$25.50+278.9%-70.7%$585.18M$9.04M-0.8340Analyst ForecastNews CoverageGap DownHigh Trading VolumeDNTHDianthus Therapeutics1.2182 of 5 stars$18.14-9.3%$54.33+199.5%-34.8%$582.75M$6.24M-7.2680PHARPharming Group2.2012 of 5 stars$8.48+2.0%$30.00+253.8%-29.1%$576.90M$297.20M-32.62280GHRSGH Research2.4442 of 5 stars$11.03-0.3%$30.86+179.8%-8.4%$573.87MN/A-13.9610Gap DownKALVKalVista Pharmaceuticals4.1851 of 5 stars$11.54-3.3%$24.83+115.2%-4.5%$573.72MN/A-3.17100Gap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeQUREuniQure2.3164 of 5 stars$10.60-15.0%$38.89+266.9%+72.3%$573.22M$27.12M-2.14500Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TRVI Competitors NUVB Competitors BCYC Competitors IMNM Competitors DNTH Competitors PHAR Competitors GHRS Competitors KALV Competitors VECT Competitors QURE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVA Stock Free IVA Stock Alerts